Deal tracker
Biopharma acquisitions, licensing deals and partnerships, updated automatically every day from company announcements and filings. Values are headline figures in US dollars, including milestone payments where disclosed.
- Deals in 2026
- 12
- Disclosed value
- $45bn
- Largest deal
- $19bn
| Announced | Buyer or partner | Target or asset | Type | Value | Status | Source |
|---|---|---|---|---|---|---|
| 11 Nov 2026 | AstraZeneca | OmnioseVaccine platform | Acquisition | Undisclosed | Completed | Source β |
| 9 Nov 2026 | Argenx | Unnatural ProductsMacrocyclic peptide discovery | Acquisition | $1.1bn$550mn upfront | Announced | Source β |
| 21 Oct 2026 | Merck KGaA | Silence TherapeuticsDivesiran | Acquisition | $1.1bn | Announced | Source β |
| 8 Oct 2026 | Viatris | Pacira BioSciences | Acquisition | $1.6bn | Announced | Source β |
| 31 Aug 2026 | Eli Lilly | Merida BiosciencesMER511 | Acquisition | $2.9bn | Announced | Source β |
| 27 Jul 2026 | Argenx | Forte BiosciencesFB102 | Acquisition | $2.2bn | Completed | Source β |
| 16 Jul 2026 | Eli Lilly | AtaiBeckleyPsychedelic medicines | Acquisition | $3.8bn | Announced | Source β |
| 29 Jun 2026 | Zymeworks | Theravance Biopharma | Acquisition | $929mn | Announced | Source β |
| 18 Jun 2026 | AbbVie | Apogee Therapeutics | Acquisition | $11bn | Announced | Source β |
